Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

NCT07416409 is registered in ClinicalTrials.gov with Deraya University as lead sponsor.

NCT NCT07416409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Lead sponsor
Deraya University
Phase
Observational
Overall status
Completed
Start date
June 10, 2023
Completion date
June 20, 2025
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, her2-positive breast cancer, metastatic breast cancer, oncology